Recent studies have also shown that anlotinib, in combination with other antitumor medications like eribulin (a novel, nontaxane microtubule dynamics inhibitor) or TQB2450 (a monoclonal antibody targeting PD-L1), demonstrates promising efficacy and manageable safety in previously treated advanced Triple-Negative Breast Cancer (TNBC) (Liu et al., 2023; Wang et al., 2023). Here, CD274 is linked to triple-negative breast carcinoma.